



## THE PREVALENCE OF ATRIAL FIBRILLATION IN EMERGENCY DEPARTMENT

**\*Firas Kahttan Abbas (MBChB, CJBAEM), Tahseen Ali Raheemah (MBChB, CABEM)**

Article Received: 05 January 2026

Article Revised: 25 January 2026

Article Published: 04 February 2026

**\*Corresponding Author: Firas Kahttan Abbas (MBChB, CJBAEM)**DOI: <https://doi.org/10.5281/zenodo.18481640>**How to cite this Article:** \*Firas Kahttan Abbas (MBChB, CJBAEM), Tahseen Ali Raheemah (MBChB, CABEM) (2026). The Prevalence of Atrial Fibrillation In Emergency Department. World Journal of Advance Healthcare Research, 10(2), 191–201.

This work is licensed under Creative Commons Attribution 4.0 International license.

**ABSTRACT****Background:** The atrial fibrillation is a common cardiac disease presented to emergency all over the world. Studying prevalence management and risk factors is important in treatment planning for atrial fibrillation. **Aim of study:** To investigate the prevalence, management and risks of atrial fibrillation in emergency department.**Patients and methods:** A prospective cross-sectional study carried out in the Emergency department of Baghdad Teaching Hospital/Medical City Complex in Baghdad city-Iraq during duration of one year from 1<sup>st</sup> of January, till 31<sup>st</sup> of December, 2023 on sample of 195 patients presented with atrial fibrillation. The atrial fibrillation was diagnosed from interpretation of a 12-lead electrocardiography showing irregularly ventricular rhythm with no discrete P wave, but low amplitude, continuously varying fibrillatory waves. **Results:** From 49,134 patients presented to emergency department, 195 (0.39%) patients had atrial fibrillation. The common treatment of atrial fibrillation patients was metoprolol and 24 (12.3%) patients were died. Factors related to death were older age, female sex, altered mental status, long chief complaint duration, heart failure history, stroke history, lasix use, high CHA2DS2 VASc score, negative electrolyte disturbances, high WBC count, low platelets count, anemia, high serum creatinine level, high serum potassium level and nor-adrenaline infusion treatment. **Conclusions:** The prevalence of atrial fibrillation in emergency department of Baghdad Teaching hospital is low.**KEYWORDS:** Atrial fibrillation, Prevalence, management, Risk factors.**INTRODUCTION**

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and its prevalence is increased by the aging population and aging-related comorbidities.<sup>[1]</sup> AF is associated with an increased risk of mortality and morbidity due to heart failure, dementia, and ischemic stroke compared to patients without AF.<sup>[2]</sup> Comorbid conditions complicated by AF caused hospitalization, and consequently, the healthcare burden associated with AF is growing.<sup>[3]</sup> Previous studies, mainly from the United States or Europe, have reported an increase in hospitalizations and total cost for AF care in recent decades.<sup>[4]</sup> In Korea, hospitalizations for AF have increased by 4.2-fold, and the total cost of care increased by about 5.7-fold over the past 10 years.<sup>[3]</sup>

While the healthcare burden of AF is mainly related to hospitalization<sup>[5]</sup>, an emergency department (ED) visit is an indicator that reflects poorly controlled AF symptoms

or complications of AF and is associated with worsened quality of life. A substantial number of patients who visit an ED are subsequently hospitalized.<sup>[6]</sup> Despite the clinical impact of ED visits in patients with AF, most epidemiologic studies have been based on Western populations, with limited data in Asian populations.<sup>[6][7]</sup>

**AIM OF STUDY**

To investigate the prevalence, management and risks of atrial fibrillation in emergency department.

**PATIENTS AND METHOD****Study design & settings**

A prospective cross-sectional study carried out in the Emergency department of Baghdad Teaching Hospital/Medical City Complex in Baghdad city-Iraq during duration of one year from 1<sup>st</sup> of January, till 31<sup>st</sup> of December, 2023.

**Study population**

All patients with atrial fibrillation presented to Emergency department of Baghdad Teaching Hospital were the study population.

**Inclusion criteria**

Adult and adolescent patients (age  $\geq 14$  years).

Cardiac or respiratory symptoms.

Atrial fibrillation.

**Exclusion criteria**

Children and adolescents.

Pregnant females.

Lack reliable history

Not completing the required investigations.

Patient lost follow up.

Patient refused to participate.

**Sampling**

A convenient sample of 195 patients presented with atrial fibrillation was selected from Emergency department of Baghdad Teaching Hospital after eligibility to inclusion and exclusion criteria.

**Data Collection**

The data were collected directly from patients filled in a prepared questionnaire in Emergency department. The questionnaire was designed by the supervisor. The following information was checked for every patient:

Sociodemographic characteristics of AF patients: Age, sex, smoking and alcohol consumption.

Chief complaint of AF patients: Chief complaint and duration of chief complaint.

Past medical history of AF patients at arrival: Hypertension, diabetes mellitus, heart failure, ischemic heart disease, valvular heart disease, transient ischemic attack/stroke and renal disease.

Drugs history of AF patients: Drugs history and drugs types.

Assessment and ECG findings of AF patients: CHA2DS2 VASc score, ECG rate, signs of ischemia, signs of electrolyte disturbances and troponin test.

Chest x-ray findings of AF patients: Infection, pulmonary edema and cardiomegaly.

Investigations findings of AF patients: WBC count, platelets count, hemoglobin level, general urine examination, random blood sugar, blood urea level, serum creatinine level and serum potassium level.

Treatment of AF patients.

Fate of AF patients.

Each patient included in this study was examined by the researcher after taking full history. AF was diagnosed

from interpretation of a12-lead ECG showing irregularly ventricular rhythm with no discrete P wave, but low amplitude, continuously varying fibrillatory waves. Previous ECG records were also reviewed when available. The investigations were done at the local emergency department laboratory. Follow up of patients was done by the researcher for duration of their stay in emergency department to assess the fate of patients.

**Ethical considerations**

Approval was taken from Arab Board of Health Specializations.

An agreement was taken from hospital authorities.

An oral informed consent was taken from patients enrolled in the study.

**Statistical analysis**

All patients' data entered using computerized statistical software; Statistical Package for Social Sciences (SPSS) version 22 was used. Descriptive statistics presented as (mean  $\pm$  standard deviation) and frequencies as percentages. Multiple contingency tables conducted and appropriate statistical tests performed, Chi square test was used for categorical variables (Fishers exact test was used when expected variable was less than 20% of total variable). Independent sample t-test was used to compare between two means. In all statistical analysis, level of significance (p value) set at  $\leq 0.05$  and the result presented as tables and/or graphs.

**RESULTS**

From 49,134 patients presented to emergency department, 195 (0.39%) patients had atrial fibrillation (AF).




Figure 1: AF prevalence in emergency department.




Figure 2: Disposition AF patients.

Common death causes of AF patients were septic shock in 8 (33.3%) patients and cardiogenic shock in 8 (33.3%) patients. (*Figure 3*)




Figure 3: Death causes of AF patients.

There was a significant association between increased age of AF patients and death disposition ( $p=0.01$ ). A significant association was observed between female sex and death of AF patients ( $p=0.05$ ). No significant

differences were observed between alive or dead AF patients regarding smoking history ( $p=0.18$ ) and alcohol consumption ( $p=0.3$ ). (Table 1)

Table 1: Distribution of sociodemographic characteristics according to fate.

| Variable                   | Disposition |      |      |       | P               |  |
|----------------------------|-------------|------|------|-------|-----------------|--|
|                            | Alive       |      | Dead |       |                 |  |
|                            | No.         | %    | No.  | %     |                 |  |
| <b>Age</b>                 |             |      |      |       |                 |  |
| <50 years                  | 11          | 6.4  | 0    | -     | <b>0.01**S</b>  |  |
| 50-59 years                | 37          | 21.6 | 0    | -     |                 |  |
| 60-69 years                | 34          | 19.9 | 10   | 41.7  |                 |  |
| ≥70 years                  | 89          | 52.0 | 14   | 58.3  |                 |  |
| <b>Sex</b>                 |             |      |      |       |                 |  |
| Male                       | 85          | 49.7 | 7    | 29.2  | <b>0.05***S</b> |  |
| Female                     | 86          | 50.3 | 17   | 70.8  |                 |  |
| <b>Smoking history</b>     |             |      |      |       |                 |  |
| Yes                        | 59          | 34.5 | 5    | 20.8  | 0.18***NS       |  |
| No                         | 112         | 65.5 | 19   | 79.2  |                 |  |
| <b>Alcohol consumption</b> |             |      |      |       |                 |  |
| Yes                        | 7           | 4.1  | 0    | -     | 0.3*NS          |  |
| No                         | 164         | 95.9 | 24   | 100.0 |                 |  |

\* Fishers exact test, \*\*Chi square test, NS=Not significant, S=Significant.

There was a highly significant association between altered mental status of AF patients and death disposition ( $p<0.001$ ). A significant association was observed between 1-3 days chief complaint duration and death of AF patients ( $p=0.02$ ). (Table 2)

**Table 2: Distribution of chief complaint according to fate.**

| Variable                           | Disposition |      |      |       | P                    |  |
|------------------------------------|-------------|------|------|-------|----------------------|--|
|                                    | Alive       |      | Dead |       |                      |  |
|                                    | No.         | %    | No.  | %     |                      |  |
| <b>Chief complaint</b>             |             |      |      |       |                      |  |
| SOB                                | 63          | 36.8 | 6    | 25.0  | <0.001* <sup>S</sup> |  |
| Altered mental status              | 29          | 17.0 | 9    | 37.5  |                      |  |
| Chest pain                         | 20          | 11.7 | 0    | -     |                      |  |
| Palpitation                        | 17          | 9.9  | 0    | -     |                      |  |
| Left hemiparesis                   | 9           | 5.3  | 0    | -     |                      |  |
| Cough                              | 7           | 4.1  | 0    | -     |                      |  |
| Hematemesis                        | 5           | 2.9  | 2    | 8.3   |                      |  |
| Diabetic foot                      | 6           | 3.5  | 0    | -     |                      |  |
| Fever                              | 4           | 2.3  | 2    | 8.3   |                      |  |
| Syncope                            | 4           | 2.3  | 2    | 8.3   |                      |  |
| Epigastric pain                    | 5           | 2.9  | 0    | -     |                      |  |
| Vomiting                           | 0           | -    | 3    | 12.5  |                      |  |
| Right hemiparesis                  | 2           | 1.2  | 0    | -     |                      |  |
| <b>Duration of chief complaint</b> |             |      |      |       |                      |  |
| <1 day                             | 14          | 8.2  | 0    | -     | 0.02* <sup>S</sup>   |  |
| 1-3 days                           | 129         | 75.4 | 24   | 100.0 |                      |  |
| >3 days                            | 28          | 16.4 | 0    | -     |                      |  |

\* Fishers exact test, S=Significant.

There was a significant association between heart failure history of AF patients and death disposition ( $p=0.05$ ). A significant association was observed between TIA/stroke history and death of AF patients ( $p=0.01$ ). No significant

differences were observed between alive or dead AF patients regarding hypertension ( $p=0.2$ ), diabetes mellitus ( $p=0.8$ ), ischemic heart disease ( $p=0.3$ ) and renal diseases history ( $p=0.06$ ). (**Table 3**)

**Table 3: Distribution of clinical history according to fate.**

| Variable                         | Disposition |      |      |      | P                   |  |
|----------------------------------|-------------|------|------|------|---------------------|--|
|                                  | Alive       |      | Dead |      |                     |  |
|                                  | No.         | %    | No.  | %    |                     |  |
| <b>Hypertension</b>              |             |      |      |      |                     |  |
| Yes                              | 122         | 71.3 | 20   | 83.3 | 0.2* <sup>NS</sup>  |  |
| No                               | 49          | 28.7 | 4    | 16.7 |                     |  |
| <b>Diabetes mellitus</b>         |             |      |      |      |                     |  |
| Yes                              | 74          | 43.3 | 11   | 45.8 | 0.8* <sup>NS</sup>  |  |
| No                               | 97          | 56.7 | 13   | 54.2 |                     |  |
| <b>Heart failure</b>             |             |      |      |      |                     |  |
| Yes                              | 65          | 38.0 | 14   | 58.3 | 0.05* <sup>S</sup>  |  |
| No                               | 106         | 62.0 | 10   | 41.7 |                     |  |
| <b>Ischemic heart disease</b>    |             |      |      |      |                     |  |
| Yes                              | 56          | 32.7 | 10   | 41.7 | 0.3* <sup>NS</sup>  |  |
| No                               | 115         | 67.3 | 14   | 58.3 |                     |  |
| <b>History of TIA/stroke</b>     |             |      |      |      |                     |  |
| Yes                              | 33          | 19.3 | 10   | 41.7 | 0.01* <sup>S</sup>  |  |
| No                               | 138         | 80.7 | 14   | 58.3 |                     |  |
| <b>History of renal diseases</b> |             |      |      |      |                     |  |
| Yes                              | 30          | 17.5 | 8    | 33.3 | 0.06* <sup>NS</sup> |  |
| No                               | 141         | 82.5 | 16   | 66.7 |                     |  |

\* Chi square test, \*\* Fishers exact test, S=Significant, NS=Not significant.

No significant differences were observed however, there was a significant association between lasix use by AF patients and death disposition ( $p=0.02$ ). (**Table 4**)

**Table 4: Distribution of drugs history according to fate.**

| Variable  | Disposition |      |      |      | P                   |  |
|---|-------------|------|------|------|---------------------|--|
|   | Alive       |      | Dead |      |                     |  |
|   | No.         | %    | No.  | %    |                     |  |
| <b>Drugs history</b>  |             |      |      |      |                     |  |
| Positive  | 124         | 72.5 | 13   | 54.2 | 0.06* <sup>NS</sup> |  |
| Negative  | 47          | 27.5 | 11   | 45.8 |                     |  |
| <b>Drugs types</b>  |             |      |      |      |                     |  |
| No  | 47          | 27.5 | 11   | 45.8 | 0.02** <sup>S</sup> |  |
| Keppra & warfarin   | 8           | 4.7  | 0    | -    |                     |  |
| Isosorbide dinitrate, valsartan, metoprolol, clopidogrel & atrovastatin | 23          | 13.5 | 0    | -    |                     |  |
| Bisoprolol, aspixaban, carbimazole & furosemide                         | 6           | 3.5  | 0    | -    |                     |  |
| Furosemide & OHA  | 7           | 4.1  | 0    | -    |                     |  |
| OHA & digoxin   | 4           | 2.3  | 0    | -    |                     |  |
| Amlodipine & aldactone  | 4           | 2.3  | 0    | -    |                     |  |
| Lisionoprol, concur, warfarin & atrovastatin                            | 2           | 1.2  | 0    | -    |                     |  |
| Aspirin   | 15          | 8.8  | 0    | -    |                     |  |
| Furosemide  | 15          | 8.8  | 7    | 29.2 |                     |  |
| Methyl dopa, alfacalcidol, isordil, allopurinol & furosemide            | 13          | 7.6  | 0    | -    |                     |  |
| Insulin   | 12          | 7.0  | 3    | 12.5 |                     |  |
| Aspirin, digoxin, insulin & atrovastatin                                | 4           | 2.3  | 0    | -    |                     |  |
| OHA, amlodipine, rosuvastatin & clopidogrel                             | 8           | 4.7  | 3    | 12.5 |                     |  |
| Hemodialysis  | 3           | 1.8  | 0    | -    |                     |  |

\* Chi square test, S=Significant, NS=Not significant.

Mean CHA2DS2 VASc score was significantly higher among AF patients with death disposition ( $p=0.02$ ). A significant association was observed between negative electrolyte disturbances and death of AF patients

( $p=0.003$ ). No significant differences were observed between alive or dead AF patients regarding ECG rate ( $p=0.6$ ), ischemia signs ( $p=0.6$ ) and troponin test ( $p=0.1$ ). (Table 5 and Figure 3)

**Table 5: Distribution of assessment and ECG findings according to fate.**

| Variable                                 | Disposition   |      |               |      | P                     |  |
|--|---------------|------|---------------|------|-----------------------|--|
|  | Alive         |      | Dead          |      |                       |  |
|  | No.           | %    | No.           | %    |                       |  |
| <b>CHA2DS2 VASc score</b>                |               |      |               |      |                       |  |
| Mean $\pm$ SD                            | 3.7 $\pm$ 1.9 |      | 4.6 $\pm$ 1.1 |      | 0.02* <sup>S</sup>    |  |
| <b>ECG rate</b>                          |               |      |               |      |                       |  |
| Mean $\pm$ SD                            | 123 $\pm$ 32  |      | 120 $\pm$ 42  |      | 0.6* <sup>NS</sup>    |  |
| <b>Signs of ischemia</b>                 |               |      |               |      |                       |  |
| Yes                                      | 62            | 36.3 | 10            | 41.7 | 0.6** <sup>NS</sup>   |  |
| No                                       | 109           | 63.7 | 14            | 58.3 |                       |  |
| <b>Signs of electrolyte disturbances</b> |               |      |               |      |                       |  |
| Yes                                      | 8             | 4.7  | 5             | 20.8 | 0.003*** <sup>S</sup> |  |
| No                                       | 163           | 95.3 | 19            | 79.2 |                       |  |
| <b>Troponin test</b>                     |               |      |               |      |                       |  |
| Positive                                 | 12            | 7.0  | 4             | 16.7 | 0.1*** <sup>NS</sup>  |  |
| Negative                                 | 159           | 93.0 | 20            | 83.3 |                       |  |

\* Independent sample t-test, \*\* Chi square test, \*\*\*Fishers exact test, S=Significant, NS=Not significant.




Figure 3: CHA2DS2 VASc score in regard to disposition.

No significant differences were observed between alive or dead AF patients regarding infection ( $p=0.6$ ),

pulmonary edema ( $p=0.3$ ) and cardiomegaly ( $p=0.9$ ). (Table 6)

Table 6: Distribution of x-ray findings according to fate.

| Variable               | Disposition |      |      |      | P      |  |
|------------------------|-------------|------|------|------|--------|--|
|                        | Alive       |      | Dead |      |        |  |
|                        | No.         | %    | No.  | %    |        |  |
| <b>Infection</b>       |             |      |      |      |        |  |
| Yes                    | 62          | 36.3 | 10   | 41.7 | 0.6*NS |  |
| No                     | 109         | 63.7 | 14   | 58.3 |        |  |
| <b>Pulmonary edema</b> |             |      |      |      |        |  |
| Yes                    | 74          | 43.3 | 13   | 54.2 | 0.3*NS |  |
| No                     | 97          | 56.7 | 11   | 45.8 |        |  |
| <b>Cardiomegaly</b>    |             |      |      |      |        |  |
| Yes                    | 85          | 49.7 | 12   | 50.0 | 0.9*NS |  |
| No                     | 86          | 50.3 | 12   | 50.0 |        |  |

\* Chi square test, NS=Not significant.

There was a highly significant association between high WBC count of AF patients and death disposition ( $p<0.001$ ). A highly significant association was observed between low platelets count and death of AF patients ( $p=0.01$ ). There was a significant association between anemia of AF patients and death disposition ( $p=0.03$ ). A highly significant association was observed between high serum creatinine level and death of AF patients

( $p<0.001$ ). There was a highly significant association between high serum potassium level of AF patients and death disposition ( $p<0.001$ ). No significant differences were observed between alive or dead AF patients regarding general urine examination ( $p=0.06$ ), random blood sugar ( $p=0.08$ ) and blood urea level ( $p=0.4$ ). (Table 7 and Figure 3)

Table 7: Distribution of investigations findings according to fate.

| Variable                | Disposition |      |      |      | P        |  |
|-------------------------|-------------|------|------|------|----------|--|
|                         | Alive       |      | Dead |      |          |  |
|                         | No.         | %    | No.  | %    |          |  |
| <b>WBC count</b>        |             |      |      |      |          |  |
| Low                     | 4           | 2.3  | 0    | -    | <0.001*S |  |
| Normal                  | 106         | 62.0 | 4    | 16.7 |          |  |
| High                    | 61          | 35.7 | 20   | 83.3 |          |  |
| <b>Platelets count</b>  |             |      |      |      |          |  |
| Normal                  | 154         | 90.1 | 13   | 54.2 | <0.001*S |  |
| Low                     | 17          | 9.9  | 11   | 45.8 |          |  |
| <b>Hemoglobin level</b> |             |      |      |      |          |  |

|                                  |     |      |    |       |           |
|----------------------------------|-----|------|----|-------|-----------|
| Normal                           | 89  | 52.0 | 7  | 29.2  |           |
| Anemia                           | 82  | 48.0 | 17 | 70.8  |           |
| <b>General urine examination</b> |     |      |    |       |           |
| Normal                           | 130 | 76.0 | 14 | 58.3  | 0.06**NS  |
| Abnormal                         | 41  | 24.0 | 10 | 41.7  |           |
| <b>Random blood sugar level</b>  |     |      |    |       |           |
| Normal                           | 121 | 70.8 | 21 | 87.5  | 0.08**NS  |
| High                             | 50  | 29.2 | 3  | 12.5  |           |
| <b>Blood urea level</b>          |     |      |    |       |           |
| Normal                           | 4   | 2.3  | 0  | -     | 0.4*NS    |
| High                             | 167 | 97.7 | 24 | 100.0 |           |
| <b>Serum creatinine level</b>    |     |      |    |       |           |
| Normal                           | 109 | 63.7 | 2  | 8.3   | <0.001**S |
| High                             | 62  | 36.3 | 22 | 91.7  |           |
| <b>Serum Potassium level</b>     |     |      |    |       |           |
| Normal                           | 162 | 94.7 | 16 | 66.7  | <0.001*S  |
| High                             | 9   | 5.3  | 8  | 33.3  |           |

\* Fishers exact test, \*\*Chi square test, S=Significant, NS=Not significant.




Figure 4: Distribution of WBC count in regard to fate.

There was a highly significant association between nor-adrenaline infusion treatment of AF patients and death disposition ( $p<0.001$ ). (Table 8)

Table 8: Distribution of treatment according to fate.

| Variable                                       | Disposition |      |      |      | P        |  |
|--|-------------|------|------|------|----------|--|
|  | Alive       |      | Dead |      |          |  |
|  | No.         | %    | No.  | %    |          |  |
| <b>Treatment in ED</b>                         |             |      |      |      |          |  |
| Fluids & AB                                    | 14          | 8.2  | 5    | 20.8 | <0.001*S |  |
| Digoxin vial                                   | 22          | 12.9 | 0    | -    |          |  |
| Electrical cardioversion                       | 10          | 5.8  | 4    | 16.7 |          |  |
| Electrical cardioversion & Amiodarone infusion | 12          | 7.0  | 2    | 8.3  |          |  |
| AB, anti-ischemic & surgical intervention      | 2           | 1.2  | 0    | -    |          |  |
| AB, angesid & lasix                            | 12          | 7.0  | 0    | -    |          |  |
| Concur   | 11          | 6.4  | 0    | -    |          |  |
| Metoprolol                                     | 62          | 36.3 | 5    | 20.8 |          |  |

|  |   |     |   |      |  |
|--|---|-----|---|------|--|
| Metoprolol & amiodarone                            | 4 | 2.3 | 0 | -    |  |
| Anti-ischemic                                      | 3 | 1.8 | 0 | -    |  |
| Electrical cardioversion & nor-adrenaline infusion | 2 | 1.2 | 3 | 12.5 |  |
| Blood transfusion, OGD & carvedilol                | 2 | 1.2 | 0 | -    |  |
| Nebivolol  | 3 | 1.8 | 0 | -    |  |
| Amiodarone vial                                    | 3 | 1.8 | 0 | -    |  |
| Nor-adrenaline infusion                            | 0 | -   | 5 | 20.8 |  |
| Angesid  | 6 | 3.5 | 0 | -    |  |
| AB & hemodialysis                                  | 3 | 1.8 | 0 | -    |  |

\* Fishers exact test, S=Significant

## DISCUSSION

The atrial fibrillation represented a common emergency cardiovascular disease. Studying the earlier management and risk factors related to atrial fibrillation is important in saving lives and reducing the cost.<sup>[8]</sup>

In present study, the prevalence of atrial fibrillation (0.39%) among patients presented to emergency department in Baghdad Teaching hospital was (0.39%). This prevalence is relatively close to AF prevalence of (0.66%) reported by Shah et al<sup>[9]</sup> cross sectional study in Nepal on patients admitted to internal medicine emergency department. However, our study prevalence is lower than results of Salam et al<sup>[10]</sup> scoping review study which revealed that prevalence of atrial fibrillation among patients presented to emergency department of Arabic Middle East countries was ranged between 2.8% to 5.8%. Novotny et al<sup>[11]</sup> retrospective study found that 1.8% of patients presented to emergency department had a cardiac arrhythmia. This low prevalence of atrial fibrillation in our study might be attributed to increased number of Specialist Cardiac centers in Baghdad city that decreased number of AF cases presented to Baghdad Teaching hospital in addition to differences in factors related to study design and sample size differences between different studies.

In current study, more than half of AF patients were admitted to medical ward, while 24 (12.3%) patients were died. This mortality rate of AF is close to AF mortality rate of (14.1%) reported by Niederöckl et al<sup>[12]</sup> single center cohort study in Austria. However, our study mortality rate of AF is higher than results of Jackson et al<sup>[7]</sup> cross sectional study in United States of America which found that mortality rate of AF in emergency department was (0.01%). Common death causes of AF patients in our study were septic shock in 8 (33.3%) patients and cardiogenic shock in 8 (33.3%) patients. These findings are in agreement with reports of Velliou et al<sup>[13]</sup> review study in Greece which documented that common causes of death for AF patients in emergency department were septic shock and cardiogenic shock. In our study, the common treatment of AF patients was metoprolol in 67 (34.4%) patients, followed by; digoxin vial in 22 (11.3%) patients, antibiotics & fluids in 19 (9.7%) patients, electrical cardioversion in 14 (7.2%) patients, electrical cardioversion & Amiodarone in 14 (7.2%) patients, etc. These findings are close to results of Alsagaff et al<sup>[14]</sup>

study in Indonesia which reported the metoprolol, digoxin vial and electrical cardioversion as the common treatment of AF patients in emergency department.

The present study found was a significant association between increased age of AF patients and death disposition ( $p=0.01$ ). This finding coincides with results of Jasim et al<sup>[42]</sup> study in Iraq which reported that increasing age of patients is accompanied with higher incidence and death risk of atrial fibrillation. In our study, a significant association was observed between female gender and death of AF patients ( $p=0.05$ ). This finding is parallel to results of Volgman et al<sup>[15]</sup> review study in United States of America which documented higher death risk of atrial fibrillation among women as compared to men.

The current study found a highly significant association between altered mental status of AF patients and death disposition ( $p<0.001$ ). Similarly, Leo et al<sup>[16]</sup> review study in United Kingdom stated that altering mental status of AF patients is considered as poor prognosis factor. In our study, a significant association was observed between 1-3 days chief complaint duration and death of AF patients ( $p=0.02$ ). This finding is consistent with results of Shao et al<sup>[17]</sup> prospective cohort study in China which found that longer complaint of AF especially with secondary AF was accompanied with higher mortality in emergency department.

Present study found a significant association between heart failure history of AF patients and death disposition ( $p=0.05$ ). This finding is consistent with results of Oba et al<sup>[18]</sup> hospital-based retrospective observational study in Japan which revealed that preexisting heart failure is a common risk factor for death among patients with AF. In our study, a significant association was observed between TIA/stroke history and death of AF patients ( $p=0.01$ ). This finding is similar to results of Fatah et al<sup>[19]</sup> cross sectional multicenter study in Iraq which reported that 17.6% of patients with TIA/stroke had AF and the death was reported in half of these cases. Our study found a significant association between lasix use by AF patients and death disposition ( $p=0.02$ ). This finding is parallel to results of Rodríguez-Molinero et al<sup>[20]</sup> prospective cohort study in Spain.

Current study found that mean CHA2DS2 VASc score was significantly higher among AF patients with death

disposition ( $p=0.02$ ). Consistently, Wu et al<sup>[21]</sup> hospital-based prospective study in China found that CHA2DS2 VASc score is a significant predictor of death among elderly patients with atrial fibrillation. In our study, a significant association was observed between abnormal electrolyte disturbances and death of AF patients ( $p=0.003$ ). This finding is parallel to results of Rafaqat et al<sup>[22]</sup> review study in Pakistan. Our study showed that AF patients with death outcome were significantly had high WBC count, low platelets count, anemia, high serum creatinine level and high serum potassium level ( $p<0.05$ ). These findings are consistent with results of different literatures such as Rienstra et al<sup>[23]</sup> study in United States of America and Tongyoo et al<sup>[24]</sup> prospective cohort study in Thailand.

In present study, there was a highly significant association between nor-adrenaline infusion treatment of AF patients and death disposition ( $p<0.001$ ). This finding coincides with results of Na et al<sup>[25]</sup> retrospective review study in South Korea which reported that nor-adrenaline was not reducing risk of mortality or arrhythmia among patients with cardiogenic shock, but reduced the need for additional vasopressors.

## CONCLUSIONS

The prevalence of atrial fibrillation in emergency department of Baghdad Teaching hospital is low.

The common treatment of patients with atrial fibrillation is the metoprolol.

The mortality rate of patients with atrial fibrillation in emergency department of Baghdad Teaching hospital is (12.3%).

Common death causes of patients with atrial fibrillation are septic shock and cardiogenic shock.

Risk factors for death in patients with atrial fibrillation are older age, female sex, altered mental status, long chief complaint duration, heart failure history, stroke history, lasix use, high CHA2DS2 VASc score, negative electrolyte disturbances, high WBC count, low platelets count, anemia, high serum creatinine level, high serum potassium level and nor-adrenaline infusion treatment.

## REFERENCE

1. Chao TF, Liu CJ, Tuan TC, Chen TJ, Hsieh MH, Lip GYH, et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study. *Chest*, 2018; 153(2): 453–66.
2. Lee E, Choi EK, Han KD, Lee H, Choe WS, Lee SR, et al. Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study. *PLoS One*, 2018; 13(12): e0209687.
3. Kim D, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through, 2015. *Heart*, 2018; 104(24): 2010–7.
4. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. *Circ Cardiovasc Qual Outcomes*, 2011; 4(3): 313–20.
5. Patel NJ, Deshmukh A, Pant S, Singh V, Patel N, Arora S, et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through, 2010: implications for healthcare planning. *Circulation*, 2014; 129(23): 2371–9.
6. Rozen G, Hosseini SM, Kaadan MI, Biton Y, Heist EK, Vangel M, et al. Emergency department visits for atrial fibrillation in the United States: trends in admission rates and economic burden from, 2007 to, 2014. *J Am Heart Assoc*, 2018; 7(15): e009024.
7. Jackson SL, Tong X, Yin X, George MG, Ritchey MD. Emergency department, hospital inpatient, and mortality burden of atrial fibrillation in the United States, 2006 to, 2014. *Am J Cardiol*, 2017; 120(11): 1966–73.
8. Sacchetti A, Williams J, Levi S, Akula D. Impact of emergency department management of atrial fibrillation on hospital charges. *West J Emerg Med*, 2013; 14(1): 55.
9. Shah SP, Sah RP, Panthi S, Shah RK, Acharya R, Neupane D, et al. Atrial fibrillation among patients admitted to the department of internal medicine in a tertiary care centre: a descriptive cross-sectional study. *JNMA J Nepal Med Assoc*, 2022; 60(253): 756.
10. Salam AM, Kaddoura R, Salih V, Asopa S. Atrial fibrillation in Middle Eastern Arabs and South Asians: a scoping review., 2021.
11. Novotny J, Klein MM, Haum M, Fichtner SR, Thienel MB. Prevalence of pathological arrhythmia in patients triaged to “cardiac arrhythmia” in the emergency department: a preliminary study. *Int J Emerg Med*, 2022; 15(1): 49.
12. Niederöckl J, Schwameis M, Herkner H, Domanovits H. Excess short-term mortality in noncritical patients with atrial fibrillation presenting to the emergency department. *Wien Klin Wochenschr*, 2021; 133(15): 802–5.
13. Velliou M, Sanidas E, Diakantonis A, Ventoulis I, Parassis J, Polyzogopoulou E. The Optimal Management of Patients with Atrial Fibrillation and Acute Heart Failure in the Emergency Department. *Medicina (B Aires)*, 2023; 59(12): 2113.
14. Alsagaff MY, Susilo H, Pramudia C, Juzar DA, Amadis MR, Julario R, et al. Rapid atrial fibrillation in the emergency department. *Heart Int*, 2022; 16(1): 12.
15. Volgman AS, Benjamin EJ, Curtis AB, Fang MC, Lindley KJ, Naccarelli G V, et al. Women and atrial fibrillation. *J Cardiovasc Electrophysiol*, 2021; 32(10): 2793–807.
16. Leo DG, Ozdemir H, Lane DA, Lip GYH, Keller SS, Proietti R. At the heart of the matter: how mental stress and negative emotions affect atrial fibrillation. *Front Cardiovasc Med*, 2023; 10: 1171647.
17. Shao X, Yang Y, Zhu J, Yu L, Liu L. Increased

mortality in patients with secondary diagnosis of atrial fibrillation: Report from Chinese AF registry. *Ann Noninvasive Electrocardiol*, 2020; 25(5): e12774.

- 18. Oba K, Shinjo T, Tamashiro M, Matsuoka M, Arasaki O, Arima H, et al. Cause of Death and Associated Factors in Elderly Patients With Atrial Fibrillation—Long-Term Retrospective Study—. *Circ Reports*, 2020; 2(9): 490–8.
- 19. Fatah HT, Ahmed FJ, Kakamad FH. Prevalence of atrial fibrillation among patients with ischemic stroke. *Edorium J Neurol*, 2017; 4: 1–5.
- 20. Rodríguez-Molinero A, Miñarro A, Narvaiza L, Gálvez-Barrón C, Gonzalo León N, Valldosera E, et al. Mortality in Elderly Patients Taking Furosemide: Prospective Cohorts Study. *Int J Hypertens*, 2022; 2022(1): 4708259.
- 21. Wu Y, Wang G, Dong L, Qin L, Li J, Yan H, et al. Assessment of the CHA2DS2-VASc Score for the Prediction of Death in Elderly Patients with Coronary Artery Disease and Atrial Fibrillation. *Front Cardiovasc Med*, 2021; 8: 805234.
- 22. Rafaqat S, Rafaqat S, Khurshid H, Rafaqat S. Electrolyte's imbalance role in atrial fibrillation: pharmacological management. *Int J Arrhythmia*, 2022; 23(1): 15.
- 23. Rienstra M, Sun JX, Magnani JW, Sinner MF, Lubitz SA, Sullivan LM, et al. White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study). *Am J Cardiol*, 2012; 109(4): 533–7.
- 24. ongyoo S, Viarasilpa T, Permpikul C. Serum potassium levels and outcomes in critically ill patients in the medical intensive care unit. *J Int Med Res*, 2018; 46(3): 1254–62.
- 25. Na SJ, Yang JH, Ko RE, Chung CR, Cho YH, Choi KH, et al. Dopamine versus norepinephrine as the first-line vasopressor in the treatment of cardiogenic shock. *PLoS One*, 2022; 17(11): e0277087.